On this episode of The BioHub, Amber Hayes is joined by Michael Fenn, Chief Business Officer at Bexorg, a precision neurology company combining AI with a pioneering whole-human brain platform to transform CNS drug discovery.

Michael brings experience spanning biotech investing, business development and company building, including previous roles at Dewpoint Therapeutics and Iaso Ventures. He shares his journey across the industry, what attracted him to Bexorg, and why he believes the company’s approach could fundamentally change how neurological therapies are discovered and developed.

We discuss the challenges of translating neuroscience research into effective treatments, how Bexorg is combining human brain pharmacology with AI to bridge the gap between preclinical research and clinical success, and the opportunities and challenges of building a platform-driven biotech.

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Max Brennan - Biotech HeadHunter. Innehållet i podden är skapat av Max Brennan - Biotech HeadHunter och inte av, eller tillsammans med, Poddtoppen.